Mesoblast Limited (MESO)

Market Cap	1.88B +39.3%
Revenue (ttm)	65.38M +1,053.2%
Net Income	-94.37M
EPS	-0.07
Shares Out	1.29B
PE Ratio	n/a
Forward PE	111.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,577
Open	14.40
Previous Close	14.52
Day's Range	14.27 - 14.41
52-Week Range	9.88 - 21.50
Beta	0.79
Analysts	Buy
Price Target	35.00 (+142.89%)
Earnings Date	Feb 26, 2026

About MESO

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: MESO
• Website: https://www.mesoblast.com

Financial Performance

In fiscal year 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for MESO stock is "Buy." The 12-month stock price target is $35.0, which is an increase of 142.89% from the latest price.

Price Target

$35.0

(142.89% upside)

Analyst Consensus: Buy